The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis.
about
Update on treatment of light chain amyloidosisRecent advances in the diagnosis and management of cirrhosis-associated cardiomyopathy in liver transplant candidates: advanced echo imaging, cardiac biomarkers, and advanced heart failure therapiesRationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosisThe mosaic of the cardiac amyloidosis diagnosis: role of imaging in subtypes and stages of the disease.Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis.Prognostic value of high-sensitivity cardiac troponin T in patients with endomyocardial-biopsy proven cardiac amyloidosis.Amyloidosis: pathogenesis and new therapeutic options.Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operativLenalidomide Desensitization in Systemic Light-Chain Amyloidosis With Multi-Organ InvolvementActivity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.Updates in cardiac amyloidosis: a review.Al amyloidosisA phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?Effect of Remote Ischaemic Conditioning in Oncology Patients Undergoing Chemotherapy: Rationale and Design of the ERIC-ONC Study--A Single-Center, Blinded, Randomized Controlled Trial.Effectiveness of bortezomib in cardiac Al amyloidosis: a report of two cases.Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.Cardiac amyloidosis: the heart of the matter.Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis.Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.Light-chain amyloidosis: SCT, novel agents and beyond.Light chain amyloidosis 2012: a new era.Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions.Future directions in the clinical management of amyloid light-chain amyloidosis.Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.Natural history and therapy of AL cardiac amyloidosis.Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T.Emerging Advances in the Management of Cardiac Amyloidosis.Novel strategies for the diagnosis and treatment of cardiac amyloidosis.New and developing therapies for AL amyloidosis.Paraprotein-Related Kidney Disease: Glomerular Diseases Associated with Paraproteinemias.Viewing Extrinsic Proteotoxic Stress Through the Lens of Amyloid Cardiomyopathy.The search for efficient diagnostic and prognostic biomarkers of heart failure.New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis.Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac responsePlasma hepatocyte growth factor is a novel marker of AL cardiac amyloidosis.Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis.Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis.Evaluation of patients with cardiac amyloidosis using echocardiography, ECG and right heart catheterization.
P2860
Q26829735-3FE9B49A-05A1-4557-B925-F66563299A63Q27002436-F9362A88-DB75-48D4-8E96-AFFEFD124D7CQ28069975-67024A92-B9EC-4550-A5F6-843C04575717Q30847650-A5222AD5-A12F-4044-A83D-8BCF311F6B39Q33417805-0B96E974-E9BB-48E4-8735-4714D2B36549Q33826546-55BDAADA-BECD-4ED0-8073-BD9A95B2671CQ35111771-E21C16F1-52C9-473A-8F80-DCB254A21C16Q35571048-FB21E11E-0D99-42AB-8F47-A6987C5E0C8CQ36009723-09686645-3F93-4760-B6DF-6B2B701BFF86Q36015183-2A6AC52B-D02C-4EC0-B52B-5D74996210D0Q36366356-F07ABE62-2B20-473C-8283-89FF98003BB8Q36392233-C5DE944F-3884-4911-9922-C83412988C1BQ36862339-FF107271-32B7-48C3-95DB-889AFE622119Q36892637-DE38FC89-341B-41A7-937B-91D73186341FQ36894836-651D59A6-EAC2-4322-A0F7-94104C37F261Q37673360-597320B8-9AA1-4807-BA56-0C31EF22C510Q37676296-0562062D-7C84-46ED-B2FD-4283EF88CA6BQ37899075-3C0AEB52-0E24-4F27-A86B-23B2DBF64BADQ37904673-80A25E96-96A3-401F-8ED6-BEBAA813D446Q37999957-72F15973-72F3-4508-8ECB-5BA42F100562Q38056010-FF99B336-C645-4CDE-954F-BAADFE709CEFQ38072108-08F63138-C9D2-4DAF-AF42-5104E2A5CAC3Q38168869-62AED7DE-8F50-431A-A063-E933D0659120Q38172998-2472EB55-B283-43CE-A0CA-582B9832272BQ38244397-F88BEF5D-FEAA-4222-BA08-220CBE5A9385Q38275212-4146BFF5-84FE-4E5F-BBF7-BCD0331E8E79Q38370866-718AE9F1-AD14-4D6F-BCCC-E45EA8641C67Q38587648-26BE3750-ADA4-4DD9-A344-4989060E321AQ38614967-7E702469-8466-4999-9BFA-D848DC15F4EFQ38779623-26E53318-AD2E-46FA-A4F7-897AFE7E6D72Q38831139-DDCC7EA6-A134-46A0-9694-6BF464469AD6Q38851025-78416E5E-523E-42AE-A69B-F28E1117D409Q38879246-2DAB0C2B-8986-4AC8-9C5D-7C3F63A80A61Q39024208-12435742-53F2-4530-AD7F-DB9C7C8F29A1Q39272596-B4D3781F-208B-450E-A47D-04A8037DE676Q40491689-B5A0CC60-70ED-4EF1-83A7-A78332160771Q41593651-16D09060-E39D-4476-B4B1-8A610C630BF2Q44248482-30A88BB4-4C94-46F4-914A-A427802F2BE7Q44538488-2B47FF25-A44B-4C00-9669-136C55C1E9CEQ45844390-386CD194-56E8-4CAB-B6C7-57583019E515
P2860
The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
The combination of high-sensit ...... ts survival in AL amyloidosis.
@en
The combination of high-sensitivity cardiac troponin T
@nl
type
label
The combination of high-sensit ...... ts survival in AL amyloidosis.
@en
The combination of high-sensitivity cardiac troponin T
@nl
prefLabel
The combination of high-sensit ...... ts survival in AL amyloidosis.
@en
The combination of high-sensitivity cardiac troponin T
@nl
P2093
P50
P1433
P1476
The combination of high-sensit ...... ts survival in AL amyloidosis.
@en
P2093
Andrea Foli
Gabriele Sarais
Gian Vico Melzi d'Eril
Letizia Zenone Bragotti
Paola Russo
Remigio Moratti
Riccardo Albertini
Rosana Pacciolla
P304
P356
10.1182/BLOOD-2010-05-286567
P407
P50
P577
2010-07-19T00:00:00Z